The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of Phase I (Cytochrome P450s), Phase II metabolizing enzymes and transporter genes in response to stimulation from xenobiotics, including prescription drugs. PXR and CAR knockout and humanized mouse models have proven useful. However, the rat being bigger in size, is a preferred model system for studying drug metabolism and pharmacokinetics. Here, we report the creation and preliminary characterization of PXR and CAR knockout rats and PXR/CAR double knockout rats. Whereas the expression of phase I and II enzymes and transporter genes were not upregulated by nuclear receptor-specific agonists PCN and TCPOBOP in the knockout rats, confirming the disruption of respective nuclear receptor(s), our data demonstrate that PXR appears to suppress the basal expression levels of Cyp2b2, Cyp3a23/3a1, Cyp3a2, Cyp3a18 and Ugt2b1 genes, while CAR maintains Cyp2b2 and Ugt2b1 and suppresses Cyp3a9 basal expression levels. In wild type rats, agonist binding of the nuclear receptors relieves the suppression, and target genes are expressed at levels comparable to knockout rats, with or without drug treatment. Overall, our findings are in good agreement with data obtained from human primary hepatocytes, nuclear receptor knock-out cell lines and mouse knock-out models. We believe these models are a useful complement to their mouse counterparts for drug development and as importantly, for functional studies on metabolic pathways involving nuclear receptors.
DMD # 75788 and 1-30 mg/kg respectively. Sixteen hours after injection, rats were euthanized and liver tissues were collected for RNA purification: WT vehicle (n=9), WT PCN and TCPOBOP (n=6) qRT-PCR. Liver samples were homogenized in TRIzol Reagent (Life Technologies, USA) with ceramic beads using a Precellys homogenizer (PeqLab, Germany.). Total RNA was isolated from homogenate and 100 µg of total RNA was DNAse-I treated and purified (RNA Clean-up) using
an RNeasy Mini-kit (Qiagen, USA). First strand cDNA was synthesized from 1µg of purified RNA using the RT 2 First Strand Kit from RT 2 Profiler PCR Array System (Qiagen). First strand cDNA was used in a customized RT 2 Profiler TM PCR Array (Gene list in Supplemental Table 1 ). All quantitative PCR reactions were performed following the manufacturer's recommended conditions on Bio-Rad's CFX96 Real-Time PCR Detection System. For data analysis of the RT 2 Profiler TM PCR Array, the Ct cutoff was set at 35 (limit of detection) and the average ∆Ct was calculated with normalizing to five reference genes (Rplp1, Hprt1, Rpl13a, Ldha, ActB) for each biological replicate.
Taqman assays (Supplemental Table 2 ; ThermoFisher, USA) for Phase II enzymes and transporters were performed as single-plex reactions following the manufacturer's recommended conditions on Bio-Rad's CFX96 Real-Time PCR Detection System. Biological cDNAs were pooled and assayed in triplicate. Average fold-change was calculated normalizing to three reference genes (ActB, Hprt1 and Gapdh).
For rat PXR and CAR cDNAs, synthesis was performed as above with replacing the kit's random primers with Oligo(dT)20 Primer (ThermoFisher, USA), followed by PCR amplification with the following specific oligonucleotides PXR 5ʹ-ATGAGACCTGAGGAGAGG-3ʹ and 5ʹ-DMD # 75788 used to establish a homozygous colony. A simple PCR at the target site is used as a convenient genotyping screen to differentiate between wild type (WT), heterozygotes and homozygotes alleles (Supplemental Figure 1 ). Both deletions in PXR and CAR (Supplemental Figure 2A ), led to a frameshift in the coding sequence that resulted in pre-mature termination of protein translation in the DNA binding domain (Supplemental Figure 2B) . Animals homozygous for the respective deletions are referred to as PXR -/-and CAR -/-rats, and their crossbreeds, PXR -/-/CAR -/-rats.
Confirmation of PXR and CAR gene disruption.
To find out whether the frameshift deletions in PXR -/-and CAR -/-rats led to mRNA degradation via the nonsense mediated decay pathway, we performed quantitative RT-PCR on RNA extracted from liver tissue. Comparable levels of PXR and CAR mRNAs were detected in their respective knockout models as compared to WT rats (data not shown). The deletions did not result in PXR or CAR mRNA degradation via nonsense mediated decay pathway. However, we were able to demonstrate that both mRNAs contain deletions that lead to out-of-frame translation of the messages and nonfunctional proteins (Supplemental Figure 3 ; Sequence verification of cloned cDNAs amplified with PXR or CAR specific oligonucleotides from WT, PXR -/-and CAR -/-liver RNA).
We then performed Western Blots using a monoclonal antibody raised specifically against the Nterminus of the rat PXR protein (Supplemental Figure 4A -B) on liver protein extracts. Here, we demonstrated that the major PXR peptide was detected in WT rats but absent in PXR -/-samples ( Figure 1C ), indicating PXR gene disruption by the ZFN-introduced frame-shift. We were unable to find a suitable specific antibody to detect the rat CAR protein in liver extracts.
This article has not been copyedited and formatted. The final version may differ from this version. (Figure 2A ). Female PXR -/-rats were heavier and CAR -/-rats lighter than wild-type rats (t-test; p-value <0.02; Figure 2B ) and PXR -/-/CAR -/-rats were indistinguishable from wild type rats ( Figure 2B ). However, we have to point out that these wild type and knockout rats were not measured within the same time period or same season of the year, which may cause some variability. We superimposed our weight curves onto the wild type rat weight curves available from the vendor webpage, and all the weights fell within the range of 2 standard deviations from the mean (Supplemental Figure 5) . We need to be cautious with our conclusions on relative weight change, but believe the general trend is reliable. The prototypical cytochrome P450 genes regulated by PXR and CAR, Cyp2b and the Cyp3a subfamily members were analyzed in Figure 3 and Supplemental mRNA was reduced to about 1/10 th of the WT level ( Figure 3A ). Cyp3a1/3a23, Cyp3a18 and Figure 3E ). Supplemental Table 3 is a detailed statistical analysis of basal expression levels for these five genes. In the meantime, no significant change in the basal expression level of the other genes within the array, including Cyp1a2, Abcb1a (Mdr1a), Abcb4 (Mdr2), Abcc1 (Mrp1), Abcc2 (Mrp2) and Abcc3 (Mrp3) as an example, was observed (Left cluster; Supplemental Figure   6 ).
Regulation of hepatic
The chemical activation of the rat Cyp2b2 and Cyp3a subfamily members Cyp3a23/3a1, Cyp3a18, Cyp3a2 upon the administration of PCN over vehicle treatment was observed in WT rats and CAR -/-rats, as expected for a PXR agonist (Middle clusters in Figure 3A -E; Table 1 ). The increased induction of Cyp2b2 by PCN observed in the CAR -/-rats compared to WT rats reflects the activation by PXR upon PCN treatment which compensates for the reduced CAR-dependent basal expression ( Figure 3A ). Interestingly, Cyp3a9 expression was activated by PCN in WT and PXR -/-and with no significant change in CAR -/-rats (Middle clusters in Figure 3E ; Table 1 ). At the same time, expression levels of Cyp1a2, Abcb1a, Abcb4, Abcc1, Abcc2 and Abcc3 (other genes within the array; data not shown), were unchanged upon PCN treatment in all models (Middle cluster;
Supplemental Figure 6 ).
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and Abcc3 (other genes within the array; data not shown), were not affected by TCPOBOP treatment in any of the models (Right cluster; Supplemental Figure 6 ).
Regulation of hepatic transporters and Phase II enzymes in WT, PXR -/-and CAR -/-male rats
Solute carrier (Slc) transporters Slco1a1 (Oatp1), Slco1a2 (Oatp2) Slc47a1 (Mate1) and Slc10a1
(Ntcp) were not assayed on the array. We screened RNAs from WT, PXR -/-, CAR -/-and PXR -/-/CAR -/-rats for changes in basal and activated (PCN and TCPOBOP treatment) expression levels for these transporters separately (Figure 4 ; statistical analysis Supplemental Table 3 and Table 1 and 2; Taqman assays, Supplemental Table 2 ). Oatp2 was activated 3-to 4-fold by PCN treatment in WT and CAR -/-rats and unchanged in PXR -/-and PXR -/-/CAR -/-(Middle cluster; Figure 4A ).
There were no observed changes to Oatp1 and Ntcp transporter mRNA levels (Figure 4 B, C) and Mate1 was undetected in our assay (data not shown). In addition, no significant changes were observed in basal expression level or by TCPOBOP treatment in WT or any of the KO models (Left and Right clusters, Figure 4A -C, Table 2 ).
Phase II enzymes UDP-glucuronosyltransferase (Ugt1a6, Ugt2b1 and Ugt2b7), sulfotransferase (Sult2a2), Glutathione transferase (Gstm4) and Ephx1 basal and activated mRNA levels were determined using the same methods. Basal expression levels of Ugt2b1 was trending down 2-fold in CAR -/-and upregulated ~4-fold in PXR -/-and PXR -/-/CAR -/-rats and no observed changes in Ugt1a6 when compared to WT (Left clusters; Figure 5A and B; Supplemental Table 3 ). No significant changes were observed during PCN or TCPOBOP activation (Middle and right clusters; Figure 5A and B) and Ugt2b7 was undetected in our assay (data not shown). Sult2a2 was activated Figure 5C and Figure 5D ) and we observed no changes in Gstm4 mRNA levels ( Figure 5E ).
Discussion:
In this study, we generated and characterized new knockout rat models for the nuclear receptors PXR and CAR. We observed changes in body weight, basal gene expression levels and loss of receptor mediated activation via exogenous ligands within these knockout lines.
Body weight change in the knockout models confirms the involvement of the nuclear receptors in metabolic pathways other than xenobiotic detoxification. In both genders, disruption of PXR led to weight gain, although in male rats the increase was not statistically significant. In addition, the male double KO rats were significantly lighter than wild type, whereas female double KO rats were comparable to wild type counterparts. The overall trend in rats is that disruption of PXR and CAR had an opposite effect on weight. This suggests that these nuclear receptors function on regulating basal expression levels of opposing sets of genes contributing to body mass. Their effect canceled each other out in the female rats. Similar observations on gender differences were made in mice (Uppal et al., 2005; Anakk et al., 2007) , raising the question of whether it is sufficient to only use males for pharmacological tests as the standard method currently. Regardless, weight change is the first indication that the function of these genes were in fact altered in the knockout animals.
As expected, we observed upregulation of Cyp2b2, Cyp3a23/3a1, 3a18, 3a2, 3a9, Slco1a2 (Oatp2) and Sult2a2 genes by PCN compared to by vehicle in WT rats, but not in PXR -/-(Cyp3a9 the is PXR dependent. This confirms that hepatic regulation of these genes in rats by PCN is PXRdependent. We also observed a slight induction of Ephx1 under TCPOBOP activation in PXR -/-(Right cluster, Figure 5D ) when compared to WT vehicle treated rats. However, this was not significant when comparing to vehicle treated PXR -/-rats, more than likely due to the slight increase in endogenous Ephx1 levels in these models.
Basal gene expression levels of Cyp2b2, Cyp3a23/3a1, 3a18, 3a2, and Ugt2b1 were increased in PXR -/-rats. Xie et al (2000) first reported on a PXR-null mouse and observed no changes in Cyp3a11 expression levels. However, subsequent studies around PXR in both mice and humans reported changes in genes closely related to the rat counterparts assessed in the current study. In PXR-null mice, Cyp3a11, Oatp2 and Mrp3 had higher basal mRNA levels in the liver than in wild of several drug metabolizing and transporter genes (Li et al., 2016) . In CAR knockout mice, Cyp2b13 (the mouse of equivalent of rat Cyp2b21) expression was upregulated, whereas Cyp2b10
(the mouse equivalent of rat Cyp2b2) expression was down-regulated (Hernadez et al., 2010) . In addition to changes in P450 levels, some Phase II enzymes and transporter mRNA expression levels were altered gender dependently in the liver and small intestine of PXR and CAR knockout mice (Cheng and Klaassen, 2006; Aleksunes and Klaassen, 2012 (Aleksunes and Klaassen, 2012) . Our observation on the regulation of Ugt2b1 at the endogenous level by both receptors in male rats may be species specific.
The major CYP3A metabolizing enzyme and PXR responsive gene in humans is CYP3A4, Cyp3a11 in mice and Cyp3a23/3a1 in rats. The rat Cyp3a9 is conserved across the other CYP3A
"minor" subfamily members in mice (82% identity to Cyp3a13; 65% to Cyp3a11; tblastn, data not shown) and humans (76% to CYP3A7; 75% to CYP3A5; 69% to CYP3A43; 65% to CYP3A4; tblastn, data not shown). et al., 2016) . This suggests that some of the minor CYP3A
family members are more CAR dependent than PXR, which regulates the major CYP3A family member across several species.
In summary, as expected, no nuclear receptor-specific agonist-mediated induction of Phase I and Phase II drug/xenobiotic metabolizing enzymes and transporter genes were observed in these knockout rats. Our results also suggest that PXR and CAR are involved in regulation of the basal expression level of different yet overlapping sets of drug metabolizing genes. When both PXR and CAR regulate a given gene, their effects are often counteractive, indicative of crosstalk between the two nuclear receptors. The regulation and signaling crosstalk between PXR and CAR has been linked to several other genes via protein-protein interactions (for review see Oladimeji et al., 2016; Pavek, 2016 ). This suggests we should look beyond PXR and CARs xenobiotic function and broaden our search for genes involved in other pathways that may be potentially disrupted by the loss of these protein-protein interactions.
This article has not been copyedited and formatted. The final version may differ from this version. Isogenic knockout models provide the perfect tool to dissect functions of individual genes, and these models are also useful in determining drug efficacy with or without nuclear receptors and whether inhibiting NRs would increase efficacy. PXR and CAR are both also drug targets themselves (Cheng et al., 2012; Gao and Xie, 2012; Banerjee et al., 2014) . A full understanding of all the pathways the nuclear receptors are involved in would be critical for therapeutic success.
Whereas our data only looked at a small portion of pathways PXR and CAR regulate: primarily Phase I and Phase II drug/xenobiotic metabolizing enzymes and transporter expression levels, many other targets may be regulated completely differently. Whole genome RNA profiling in different tissues of wild type and knockout animals would be highly informative on all pathways PXR and CAR are involved in and allow one to better predict metabolism of new drugs as well as potentially target PXR and CAR for therapeutics.
In the meantime, our data showed good correlation between the rat and human responses upon nuclear receptor disruption. These models complement the current mouse models. However, the rat has the advantage of size, and therefore ease of use and precision of measurements. Further studies will be needed to determine the advantage of these rat models over their mouse counterpart.
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